title: Outcomes after right-side heart sarcoma resection.
abstract: BACKGROUND
  In patients with primary cardiac sarcoma, the tumor's location is more important than cell type in determining patient presentation, therapy options, and outcomes. The purpose of the current study was to investigate the outcomes after right-side heart sarcoma resection.
  
  
  METHODS
  Clinicopathologic data from patients who underwent right-side heart sarcoma resection at our institution and patients identified in a literature search were examined. Morbidity and the 30-day mortality rate and survival were determined. We used univariate and multivariate analyses to identify independent predictors of overall survival.
  
  
  RESULTS
  We identified 57 patients who underwent right-side heart sarcoma resection. Right-side heart failure was the most common complication (4 patients, 19%), and the 30-day mortality was 14% (3 patients). The overall 5-year survival rate was 17%, and the median overall survival duration was 9 months. Multivariate analyses revealed that surgical margin status was the only independent predictor of survival. Patients with negative surgical margins had a longer median overall survival duration (27 months versus 4 months) and a significantly higher overall 5-year survival rate (36% versus 0%; p = 0.0003) than patients with positive surgical margins.
  
  
  CONCLUSIONS
  The patients with right-side heart sarcoma resection had worse survival after resection than that reported for our patients who underwent resection for left-side heart sarcoma or pulmonary artery sarcoma. Because positive surgical margin status is an independent predictor of reduced survival, induction chemotherapy should considered to enhance resectability in right-side heart sarcoma patients, thus maximizing the possibility of obtaining negative surgical margins.
authors.affiliation: Department of Surgery, Methodist Hospital, Houston, Texas, USA.
authors.forename: Min P
authors.initials: MP
authors.lastname: Kim
authors.forename: Arlene M
authors.initials: AM
authors.lastname: Correa
authors.forename: Shanda
authors.initials: S
authors.lastname: Blackmon
authors.forename: Gabriela
authors.initials: G
authors.lastname: Quiroga-Garza
authors.forename: Donald
authors.initials: D
authors.lastname: Weilbaecher
authors.forename: Brian
authors.initials: B
authors.lastname: Bruckner
authors.forename: Basel
authors.initials: B
authors.lastname: Ramlawi
authors.forename: David C
authors.initials: DC
authors.lastname: Rice
authors.forename: Ara A
authors.initials: AA
authors.lastname: Vaporciyan
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Reardon
mesh_terms: D000328:Adult; D006348:Cardiac Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006338:Heart Neoplasms / Q000401:mortality / Q000601:surgery*; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D012509:Sarcoma / Q000401:mortality / Q000601:surgery*; D015996:Survival Rate / Q000639:trends; D013781:Texas / Q000453:epidemiology; D016896:Treatment Outcome